NF1突变黑色素瘤依肿瘤起源呈现不同临床特征并对免疫检查点抑制剂应答良好
本研究分析了266例NF1突变黑色素瘤患者的多中心肿瘤组织样本,进行TERT启动子及29个相关基因的靶向二代测序,并与432例NF1野生型队列比较生存。多数NF1突变黑色素瘤发生于60岁以上患者头颈区域,NF1突变肿瘤基因突变数及UV特征C>T和CC>TT转换数高于BRAF、RAS和三野生型黑色素瘤。IV期疾病总生存在NF1突变型与野生型间相当,但接受一线免疫检查点抑制剂治疗者中NF1突变型中位总生存优于野生型(未达到 vs 25.82,p=0.0154,n分别为80和432)。
要点
- NF1突变黑色素瘤多发生于60岁以上患者头颈区域,NF1改变常为失活性突变。
- 肢端和黏膜NF1突变黑色素瘤女性多见(分别69%和83%),非肢端皮肤型男性多见(73%)。
- 一线免疫检查点抑制剂治疗者中NF1突变型中位总生存优于野生型(未达到 vs 25.82,p=0.0154)。
核心结论
- 皮肤、肢端和黏膜NF1突变黑色素瘤在临床和遗传特征上存在差异,并在免疫检查点抑制治疗中显示良好结局。
研究设计与样本
- 本研究分析了来自266例NF1突变黑色素瘤患者的多中心肿瘤组织样本队列,对TERT启动子和29个相关黑色素瘤基因进行靶向二代测序。
- 生存与来自黑色素瘤组织登记项目(Tissue Registry in Melanoma project)的NF1野生型队列(n=432)进行比较。
主要发现
- 多数NF1突变黑色素瘤发生于60岁以上患者头颈区域。
- NF1改变常为失活性,主要为无义突变,较少为截短突变;非失活性NF1突变更常与激活型BRAF和RAS突变共存。
- NF1突变肿瘤基因突变数及UV特征C>T和CC>TT转换数高于BRAF、RAS和三野生型黑色素瘤。
- NF1突变肢端和黏膜黑色素瘤具有不同突变特征,女性分别占69%和83%,不同于非肢端皮肤NF1突变黑色素瘤(男73%,女27%)。
- IV期疾病总生存在NF1突变型与野生型间相当;接受一线免疫检查点抑制剂治疗者中,NF1突变型中位总生存优于野生型(未达到 vs 25.82,p=0.0154,n分别为80和432)。
临床怎么用
- 作者结论认为皮肤、肢端和黏膜NF1突变黑色素瘤在临床和遗传特征上存在差异,并在免疫检查点抑制治疗中显示良好结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: NF1-mutated tumours represent a small subset (10-15%) of melanomas, not sufficiently analysed in large clinical cohorts. This study investigated the largest multicentre collection of NF1-mutated melanomas to date. METHODS: This study analysed a multicentre tumour tissue sample cohort from 266 patients with NF1-mutated melanoma. Targeted next-generation sequencing of the TERT promoter and 29 relevant melanoma genes was performed. Survival was compared with NF1 wild-type cohorts from the Tissue Registry in Melanoma project (n = 432). RESULTS: Most NF1-mutated melanoma arose in the head-and-neck region of patients >60 years. NF1 alterations were frequently inactivating, primarily non-sense, less frequently truncating mutations. Non-inactivating NF1 mutations more frequently co-occurred with activating BRAF and RAS mutations. NF1-mutated tumours had higher numbers of gene mutations and UV signature C>T and CC>TT transitions than BRAF, RAS and triple wild-type melanomas. NF1-mutated acral and mucosal melanomas harboured a different mutation signature and were frequent in women (69% and 83%, respectively), differing from non-acral cutaneous NF1-mutated melanomas (men 73%, women 27%). Overall survival in stage IV disease was comparable for patients with NF1-mutated or wild-type melanoma. However, in patients receiving first-line immune checkpoint inhibitor treatment, better median overall survival (mOS) was observed for NF1-mutated than wild-type tumours (mOS = not reached vs mOS = 25.82, p = 0.0154, n = 80 and 432, respectively). CONCLUSIONS: Cutaneous, acral and mucosal NF1-mutated melanomas vary in clinical and genetic characteristics and demonstrate a favourable outcome on immune checkpoint inhibition therapy.
引用
- Thielmann CM, Chorti E, Matull J, et al. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. Eur J Cancer. 2021. PMID: 34742158. doi:10.1016/j.ejca.2021.09.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。